{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T15:00:12Z","timestamp":1726758012842},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.ygyno.2004.09.015","type":"journal-article","created":{"date-parts":[[2004,11,4]],"date-time":"2004-11-04T18:28:44Z","timestamp":1099592924000},"page":"67-71","source":"Crossref","is-referenced-by-count":18,"title":["Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: A Gynecologic Oncology Group Study"],"prefix":"10.1016","volume":"96","author":[{"given":"David Scott","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Blessing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Waggoner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Sorosky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Bloss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2004.09.015_bib1","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/1097-0142(19860201)57:3<530::AID-CNCR2820570321>3.0.CO;2-5","article-title":"A critical reassessment of second-look laparotomy in epithelial ovarian carcinoma","volume":"57","author":"Miller","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2004.09.015_bib2","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/0002-9378(90)90924-V","article-title":"Flow cytometric evaluation of epithelial ovarian cancer","volume":"162","author":"Barnabei","year":"1990","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2004.09.015_bib3","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/1097-0142(19920115)69:2<502::AID-CNCR2820690238>3.0.CO;2-4","article-title":"Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer","volume":"69","author":"Miller","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2004.09.015_bib4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.1992.10.4.513","article-title":"Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population","volume":"10","author":"Markman","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.09.015_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1006\/gyno.1997.4887","article-title":"Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group","volume":"68","author":"Manetta","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.09.015_bib6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1998.5016","article-title":"Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a gynecologic oncology group phase II trial","volume":"69","author":"Markman","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.09.015_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00000421-200202000-00009","article-title":"Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a gynecologic oncology group study","volume":"25","author":"Plaxe","year":"2002","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.09.015_bib8","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1200\/JCO.2001.19.12.2975","article-title":"Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study","volume":"19","author":"Fracasso","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.09.015_bib9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1006\/gyno.2000.5984","article-title":"Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A gynecologic oncology group study","volume":"79","author":"Hoffman","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.09.015_bib10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1006\/gyno.1999.5640","article-title":"Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: a gynecologic oncology group trial","volume":"75","author":"Markman","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.09.015_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0090-8258(02)00091-4","article-title":"A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a gynecologic oncology group study","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.09.015_bib12","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/ijc.2910530526","article-title":"Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro","volume":"53","author":"Pantazis","year":"1993","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2004.09.015_bib13","first-page":"269","article-title":"A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin","volume":"1","author":"Rubin","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2004.09.015_bib14","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1200\/JCO.1996.14.4.1236","article-title":"Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult patients","volume":"14","author":"Dahut","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.09.015_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/sonc.2002.31592","article-title":"Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the gynecologic oncology group (GOG-0182)","volume":"29","author":"Bookman","year":"2002","journal-title":"Semin. Oncol."},{"issue":"4933","key":"10.1016\/j.ygyno.2004.09.015_bib16","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1126\/science.2555920","article-title":"DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts","volume":"246","author":"Giovanella","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2004.09.015_bib17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/00001813-200209000-00006","article-title":"Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as fractions over 14 days","volume":"13","author":"Muggia","year":"2002","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ygyno.2004.09.015_bib18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.2004.03.016","article-title":"Biweekly 72-hour 9-aminocamptothecin infusion as a second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group","volume":"22","author":"Hochster","year":"2004","journal-title":"JCO"},{"key":"10.1016\/j.ygyno.2004.09.015_bib19","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.09.015_bib20","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jnci\/86.20.1530","article-title":"Phase II study of gemcitabine (2\u20322\u2032difluorodeoxycytidine) in previously treated ovarian cancer patients","volume":"86","author":"Lund","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2004.09.015_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","article-title":"Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel","volume":"63","author":"Shapiro","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.09.015_bib22","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel","volume":"16","author":"Bookman","year":"1998","journal-title":"JCO"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825804007371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825804007371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T11:24:05Z","timestamp":1549106645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825804007371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0090825804007371"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2004.09.015","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}